Literature DB >> 11164424

Two subpopulations of intermediate density lipoprotein and their relationship to plasma triglyceride and cholesterol levels.

B J Meyer1, M J Caslake, M M McConnell, C J Packard.   

Abstract

We observed the appearance of two intermediate density lipoprotein (IDL) subfractions on gradient gel electrophoresis of lipoproteins in the density range 1.006-1.030 g/ml and estimated their approximate concentrations in plasma in subjects with a wide range of lipid levels, from 0.55 to 28.0 mmol/l plasma triglyceride and 3.75-10.0 mmol/l cholesterol. The larger species, IDL-I (31.7 +/- 0.7 nm, mean +/- SD), showed little variation in size in normal and moderate hyperlipidaemic individuals. The estimated concentration of IDL-I was positively related to plasma triglyceride (r = 0.63, P = 0.0004) and low density lipoprotein (LDL) cholesterol (r = 0.68, P = 0.0003). These findings are consistent with the view that IDL-I is a metabolic intermediate between very low density lipoprotein (VLDL) and LDL. The smaller subfraction, IDL-II (25.7 +/- 2.4 nm) was virtually the only true species observed in subjects with plasma triglyceride < 1.0 mmol/l and its estimated concentration fell as plasma triglyceride increased (r = -0.58, P = 0.0002). IDL-II particle size changed in concert with LDL particle size (r = 0.61, P < 0.0001), suggesting that they were influenced by common metabolic factors. These observations provide further support for the hypothesis outlined by Musliner et al. [1] that IDL-I was part of the delipidation chain from VLDL to LDL, whereas IDL-II arose from a separate source, possibly directly released from the liver. Hence the two subpopulations of IDL differ in their relationship to plasma triglyceride and cholesterol levels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11164424     DOI: 10.1016/s0021-9150(00)00408-1

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  2 in total

Review 1.  Targeting triglycerides as prognostic indicators and determining lowest values for patient benefit.

Authors:  D L Sprecher
Journal:  Curr Cardiol Rep       Date:  2001-09       Impact factor: 2.931

2.  Analysis of cholesterol levels in lipoprotein(a) with anion-exchange chromatography.

Authors:  Yuji Hirowatari; Hiroshi Yoshida; Hideo Kurosawa; Yuko Shimura; Hidekatsu Yanai; Norio Tada
Journal:  J Lipid Res       Date:  2009-10-30       Impact factor: 5.922

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.